Informed Decision-Making in the Management of Bladder Dysfunction: Expert Managed Care Strategies on Overactive Bladder
 
 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2024 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2024 to August 1, 2025
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Astellas

Description:
Overactive bladder (OAB) is a highly prevalent condition that approximately 17% of women and 16% of men over 18 suffer from. OAB occurs about twice as frequently in women as in men, and while OAB is not considered a normal part of aging, it does become more prevalent with advanced age. OAB has a significant impact on quality of life (QoL), co-morbidities, and cost; sufferers are two to three times more likely to experience disturbed sleep, overeating, poor self-esteem, and depression. Despite its impact, OAB remains underdiagnosed and undertreated. Screening and evaluating patients is important in order to improve diagnosis and patient QoL. Once diagnosed, there are a variety of treatments available. There is a stepwise progression in the management of OAB and multiple options of treatment in each line of therapy, providing a tailored approach to individualize treatment based upon a patient’s expectation and goal for treatment, their co-morbidities, symptoms, and the side-effects of treatments.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of overactive bladder (OAB), including factors that contribute to poor prognosis and increased costs

  • Explore barriers that prevent patients from receiving diagnosis and effective treatment of OAB

  • Compare and contrast the efficacy and safety profiles of current therapies, including the antimuscarinics, beta-3 agonists, and combination therapy, in the management of OAB

  • Evaluate the role of novel treatments for the management of neurogenic detrusor overactivity (NDO) in pediatric patients

  • Review patient factors to consider when selecting between anticholinergics and beta-3 adrenoceptor agonists for OAB treatment
     

Faculty:
Eric S. Rovner, MD
Professor of Urology
Spaulding-Paolozzi Endowed Chair in Female Pelvic Medicine and Reconstructive Surgery
Department of Urology
Medical University of South Carolina

Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Rovner has served as a consultant for AbbVie, Bluewind, and Sumitomo. He owns stock in Urocure. He has received grant/research support from AbbVie, EG-427, and Sumitomo. All relevant conflicts of interest have been mitigated.

Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.

This activity is supported by an educational grant from
Astellas


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue